Investors
A MESSAGE FROM OUR CEO
”There are more than 400,000 newly diagnosed patients each year in the Western World of which a large fraction would benefit from treatment with resomelagon as a new effective and safe treatment option.
-
November 20, 2024 RegulatoryNotice of extraordinary general meeting in SynAct Pharma AB
-
November 20, 2024 RegulatorySynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
-
November 14, 2024 Non RegulatorySynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
The interim report for Q3 2024 was published on October 30, 2024, at 07.30 CEST.